Fig. 1: Schematic illustration of the in situ cancer vaccine composed of a biomaterial scaffold (gray circle) loaded with chemokines, adjuvants, and chemotherapeutic drugs (Dox-iRGD).
From: Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
The biomaterial is injected peritumorally, and Dox-iRGD is released to penetrate into tumors and induce immunogenic death of tumor cells, whereas released chemokines can accumulate large numbers of immature dendritic cells (DCs) at the scaffold site. Accumulated DCs can take up and process tumor antigens while being activated with adjuvants to prime tumor-specific T cells for tumor cell killing.
